Measuring US Pharmaceutical Industry R&D Spending
Government policy debates on pharmaceutical pricing often turn on whether higher drug prices fund greater company-financed R&D spending. In the US, debate breaks down because each side uses a different measure of R&D spending, and the measures are far apart. Government agencies, Congress and consumer groups use government-generated survey data from the National Science Foundation (NSF), and the pharmaceutical industry uses survey data from the Pharmaceutical Research and Manufacturers of America (PhRMA). This issue is also relevant to academic work because some studies use NSF data, and others use PhRMA data. This article illustrates the pros and cons of these survey data series, and offers a more reliable, comprehensive and replicable alternative series, based on Compustat data. Copyright Adis Data Information BV 2008
Year of publication: |
2008
|
---|---|
Authors: | Golec, Joseph ; Vernon, John |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 26.2008, 12, p. 1005-1017
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
New estimates of the cost of capital for pharmaceutical firms
Giaccotto, Carmelo, (2011)
-
Real Option Value and Path Dependence in Oncology Innovation
Cook, Joseph, (2011)
-
Economic Evaluation and Cost-Effectiveness Thresholds
Vernon, John, (2009)
- More ...